SQZ Biotechnologies Company (SQZB)
OTCMKTS: SQZB · Delayed Price · USD
0.0450
+0.0080 (21.62%)
Jul 25, 2024, 2:29 PM EDT - Market open
SQZB Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year Ending | TTM | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|
| Revenue | 12.12 | 21.48 | 27.1 | 21 | 20.11 | 12.67 |
| Revenue Growth (YoY) | -44.62% | -20.74% | 29.05% | 4.42% | 58.73% | - |
| Cost of Revenue | 51.79 | 70.98 | 70.15 | 51.55 | 36.1 | 24.38 |
| Gross Profit | -39.67 | -49.51 | -43.05 | -30.55 | -15.99 | -11.71 |
| Selling, General & Admin | 21.1 | 26.32 | 25.72 | 20.51 | 18.27 | 8.69 |
| Operating Expenses | 21.1 | 26.32 | 25.72 | 20.51 | 18.27 | 8.69 |
| Operating Income | -60.77 | -75.83 | -68.77 | -51.06 | -34.27 | -20.4 |
| Interest Expense | - | - | - | - | - | -0.06 |
| Interest & Investment Income | 1.62 | 1.22 | 0.04 | 0.55 | 2.07 | 0.98 |
| Other Non Operating Income (Expenses) | -0.07 | -0 | -0.01 | -0.01 | -0.01 | 0.24 |
| EBT Excluding Unusual Items | -59.22 | -74.61 | -68.74 | -50.52 | -32.2 | -19.25 |
| Merger & Restructuring Charges | -12.43 | -4.86 | - | - | - | - |
| Other Unusual Items | - | - | - | - | - | -0.98 |
| Pretax Income | -71.64 | -79.46 | -68.74 | -50.52 | -32.2 | -20.23 |
| Net Income | -71.64 | -79.46 | -68.74 | -50.52 | -32.2 | -20.23 |
| Net Income to Common | -71.64 | -79.46 | -68.74 | -50.52 | -32.2 | -20.23 |
| Shares Outstanding (Basic) | 29 | 29 | 28 | 5 | 2 | 2 |
| Shares Outstanding (Diluted) | 29 | 29 | 28 | 5 | 2 | 2 |
| Shares Change (YoY) | 3.56% | 4.47% | 410.54% | 216.92% | 13.12% | - |
| EPS (Basic) | -2.43 | -2.76 | -2.49 | -9.35 | -18.89 | -13.43 |
| EPS (Diluted) | -2.43 | -2.76 | -2.49 | -9.35 | -18.89 | -13.43 |
| Free Cash Flow | -74.55 | -84.07 | -82.75 | -44.33 | -35.66 | 19.79 |
| Free Cash Flow Per Share | -2.53 | -2.92 | -3.00 | -8.21 | -20.92 | 13.13 |
| Gross Margin | - | -230.50% | -158.87% | -145.48% | -79.53% | -92.43% |
| Operating Margin | -501.34% | -353.04% | -253.78% | -243.16% | -170.40% | -161.05% |
| Profit Margin | - | - | -253.68% | -240.60% | -160.14% | -159.71% |
| Free Cash Flow Margin | -615.02% | -391.43% | -305.37% | -211.11% | -177.33% | 156.22% |
| EBITDA | -59.06 | -74.32 | -67.56 | -49.72 | -32.88 | -19.34 |
| EBITDA Margin | - | - | -249.32% | -236.77% | -163.51% | -152.63% |
| D&A For EBITDA | 1.71 | 1.5 | 1.21 | 1.34 | 1.38 | 1.07 |
| EBIT | -60.77 | -75.83 | -68.77 | -51.06 | -34.27 | -20.4 |
| EBIT Margin | - | - | -253.78% | -243.16% | -170.40% | -161.05% |
| Revenue as Reported | 12.12 | 21.48 | 27.1 | - | 20.11 | 12.67 |
Source: S&P Capital IQ. Standard template.